Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
Growing
The company is in a growing phase, with the latest annual income totaling USD 56.29M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 56.29M.
Undervalued
The company’s latest PE is 3.65, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 10.05M shares, decreasing 27.59% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 31.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.24.